The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

NCT06254690 ·Status: RECRUITING ·Phase: PHASE2

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

NCT06754059 ·Status: RECRUITING

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

NCT04254263 ·Status: RECRUITING ·Phase: PHASE3

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

NCT06144944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

NCT05525767 ·Status: RECRUITING ·Phase: PHASE4

Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

NCT05263882 ·Status: UNKNOWN ·Phase: PHASE2

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

NCT07180056 ·Status: RECRUITING

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

NCT05561686 ·Status: UNKNOWN

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

NCT06495541 ·Status: NOT_YET_RECRUITING ·Phase: NA

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

NCT05572645 ·Status: COMPLETED

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

NCT04158505 ·Status: UNKNOWN

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

NCT06860529 ·Status: RECRUITING ·Phase: PHASE2

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

NCT06394661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

NCT06700369 ·Status: RECRUITING

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

NCT04900311 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

NCT06711068 ·Status: RECRUITING

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

NCT05020964 ·Status: UNKNOWN ·Phase: PHASE2

A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy

NCT06470347 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

NCT07305246 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

NCT06914661 ·Status: ENROLLING_BY_INVITATION